Good morning :)
$
₹
Jaguar Animal Health Inc

Jaguar Animal Health Inc

JAGX

NASDAQ
Asset Logo

Jaguar Animal Health Inc

JAGX

NASDAQ
$2.35—% (+2.35)
$
₹
$2.35—% (+2.35)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Unknown

Sector and industry information not available

Micro Cap

With a market cap of $2.6M the stock is ranked 6093

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.87
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-2.58
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

-0.02
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Based on 2 analysts reports

Buy
2 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+927.4%

Earnings Growth

—

Rev. Growth

—

Company Profile

Company Profile

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
42.74
42.74
1Y Return
55.33%
55.33%
Buy Reco %
83.87
83.87
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
40.03
40.03
1Y Return
37.93%
37.93%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
115.29
115.29
1Y Return
66.63%
66.63%
Buy Reco %
70.37
70.37
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
22.82
22.82
1Y Return
14.79%
14.79%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
25.78
25.78
1Y Return
1.93%
1.93%
Buy Reco %
83.33
83.33
Compare with Peers

Financials

Financials

Income

Balance Sheet

Cash Flow

Hmm, looks like data is currently unavailable. Once it's updated, you can view it here

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Jaguar Animal Health Inc -0.87-0.02
Eli Lilly and Company42.7430.781.15
Johnson & Johnson40.037.632.82
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare JAGX with any stock or ETF
Compare JAGX with any stock or ETF
Comparing from
JAGX
LLY
JNJ
Loading...

Frequently asked questions

  1. Jaguar Animal Health Inc (JAGX) share price today is $2.35 as of October 27, 2026 at 1:29 AM IST. The stock touched a day high of $2.52 and a day low of $2.01.

  2. Jaguar Animal Health Inc stock trades on NASDAQ under the ticker symbol JAGX.

  3. Jaguar Animal Health Inc's market capitalization is $2.63M as of October 27, 2026 at 1:29 AM IST.

  4. Jaguar Animal Health Inc's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. Jaguar Animal Health Inc's price-to-book (P/B) ratio is 0.87 as of October 26, 2026.

  6. Yes, You can buy Jaguar Animal Health Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Jaguar Animal Health Inc shares in three steps: 1. Search Jaguar Animal Health Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Jaguar Animal Health Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Jaguar Animal Health Inc (JAGX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 4.2462 shares at the current price of $2.35.

Loading...